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Nanoliposomal Nitroglycerin 
Exerts Potent Anti-Inflammatory 
Effects
Soroush Ardekani1, Harry A. Scott1, Sharad Gupta2,†, Shane Eum1, Xiao Yang1, 
Alexander R. Brunelle3, Sean M. Wilson3, Umar Mohideen2 & Kaustabh Ghosh1
Nitroglycerin (NTG) markedly enhances nitric oxide (NO) bioavailability. However, its ability to 
mimic the anti-inflammatory properties of NO remains unknown. Here, we examined whether 
NTG can suppress endothelial cell (EC) activation during inflammation and developed NTG 
nanoformulation to simultaneously amplify its anti-inflammatory effects and ameliorate adverse 
effects associated with high-dose NTG administration. Our findings reveal that NTG significantly 
inhibits human U937 cell adhesion to NO-deficient human microvascular ECs in vitro through an 
increase in endothelial NO and decrease in endothelial ICAM-1 clustering, as determined by NO 
analyzer, microfluorimetry, and immunofluorescence staining. Nanoliposomal NTG (NTG-NL) was 
formulated by encapsulating NTG within unilamellar lipid vesicles (DPhPC, POPC, Cholesterol, DHPE-
Texas Red at molar ratio of 6:2:2:0.2) that were ~155 nm in diameter and readily uptaken by ECs, 
as determined by dynamic light scattering and quantitative fluorescence microscopy, respectively. 
More importantly, NTG-NL produced a 70-fold increase in NTG therapeutic efficacy when compared 
with free NTG while preventing excessive mitochondrial superoxide production associated with high 
NTG doses. Thus, these findings, which are the first to reveal the superior therapeutic effects of an 
NTG nanoformulation, provide the rationale for their detailed investigation for potentially superior 
vascular normalization therapies.
Loss of endothelium-derived nitric oxide (NO), which prevents leukocyte-endothelial cell (EC) adhe-
sion, is strongly implicated in chronic inflammation associated with debilitating cardiovascular condi-
tions such as pulmonary arterial hypertension (PAH)1, atherosclerosis2, and diabetes3. Administration 
of nitrates/nitrites, which rapidly produce NO, is thus being explored as anti-inflammatory therapy4,5. 
Since organic nitrates exert superior NO-dependent vasodilatory effects when compared with inorganic 
nitrates/nitrites6, they likely also exhibit more potent anti-inflammatory effects.
Of the clinically used organic nitrates, nitroglycerin (NTG) holds particular promise as an 
anti-inflammatory drug because, in addition to spontaneously producing NO via mitochondrial aldehyde 
dehydrogenase (ALDH-2)7, it also activates endothelial NO synthase (eNOS)8,9, the key NO-producing 
enzyme in ECs that is impaired in inflammatory cardiovascular conditions3. However, despite its poten-
tial anti-inflammatory properties, NTG presents a conundrum as long-term clinical use of current NTG 
formulations (e.g. transdermal patches, tablets) results in excessive mitochondrial superoxide generation 
that leads to a loss of NTG sensitivity (tolerance) and endothelial dysfunction (cross-tolerance)10–12, 
thereby limiting its therapeutic efficacy. Thus, new NTG formulations are required to fully leverage the 
anti-inflammatory potential of NTG.
The field of nanomedicine has enabled the development of nanomaterials (liposomes and poly-
meric nanoparticles) that can greatly improve drug delivery and therapeutic efficacy by simultaneously 
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increasing drug half-life, lowering effective drug dose (IC50), and reducing toxic side-effects13,14. For 
instance, our previous work has shown that incorporation of genistein within polymeric nanoparticles 
improves its anti-inflammatory effect by over two orders of magnitude15. Thus, such a nanotherapeutic 
approach has the ability to amplify the potential anti-inflammatory effects of NTG as well as ameliorate 
the adverse effects associated with contemporary high-dose NTG administration.
Here, we first demonstrate that NTG-derived NO effectively suppresses endothelial activation during 
inflammation. Further, we developed a new nanoencapsulation approach for effective NTG delivery that 
exhibits potent anti-inflammatory effects at a dose 70-fold lower than that of free NTG while preventing 
excessive mitochondrial superoxide production associated with high NTG doses.
Results
NTG Exerts Anti-inflammatory Effects on Activated ECs. Since NTG enhances endothelial NO 
bioavailability through both spontaneous biotransformation and eNOS activation7,8, we asked whether 
NTG could mimic the anti-inflammatory property of NO. To address this question, EC monolayers were 
treated with L-NIO (5 mM), a selective eNOS inhibitor8, or TNF-α (10 ng/ml), which downregulates 
eNOS mRNA16, to impair endogenous endothelial NO production and thereby enhance monocyte-EC 
adhesion both in vitro and in pathological conditions in vivo1,3. Images of fluorescently-labeled adherent 
U937 cells and their quantification revealed that addition of NTG to L-NIO-treated ECs produces a 
dose-dependent inhibition of U937 cell adhesion to ECs (Fig. 1A,B), with the inhibition being significant 
(p < 0.01) at 5 μ M NTG dose where U937 cell adhesion was comparable with that on untreated ECs. 
Notably, NTG exerted a similar dose-dependent anti-inflammatory effect on cells activated with TNF-α 
(Fig. 1C).
NTG Enhances Endothelial NO Production. The potent and hitherto-unknown anti-inflammatory 
effect of NTG expectedly resulted from an increase in endothelial NO production, as confirmed by two 
independent approaches. Measurement of released (extracellular) NO by nitric oxide analyzer (NOA) 
revealed that addition of NTG to L-NIO-treated ECs prevented the loss of NO by L-NIO (Fig.  2A). 
These findings were independently confirmed by measurement of intracellular NO using a fluorescent 
NO-sensitive DAF-FM diacetate dye where quantification of fluorescence intensities revealed that NTG 
causes a significant (79%; p < 0.001) recovery of NO (Fig. 2B).
NO is known to suppress leukocyte-EC adhesion by inhibiting the clustering and/or expression 
of endothelial cell adhesion molecules (CAMs)17,18. Our flow cytometry measurement revealed that 
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Figure 1. NTG Exerts Anti-inflammatory Effects on Activated ECs. NTG produces dose-dependent 
inhibition of U937 monocytic cell adhesion to L-NIO-treated (5 mM; overnight) ECs, with significant 
inhibition observed at 5 μ M NTG dose and not lower (0.2 μ M and 1 μ M doses), as shown in (A) the 
fluorescence images and (B) quantified in the bar graph (n = 10 fields of view). **p < 0.01; ns, no 
significance. (C) Similar anti-inflammatory effect of NTG was observed on TNF-α -treated ECs (n = 10 fields 
of view). **p < 0.01; ***p < 0.001. Data are expressed as mean ± SEM. Scale bar: 200 μ m.
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neither inhibition of NO (using L-NIO) nor its enhancement (using NTG) altered ICAM-1 expression 
(Supplementary Fig. S1). However, quantitative analysis of fluorescent images of U937 cell-EC co-cultures 
labeled with anti-ICAM-1 antibody and phalloidin (which stains actin cytoskeleton) revealed that 
NTG prevents the significant increase (1.6-fold; p < 0.001) in ICAM-1 clustering seen on NO-deficient 
(L-NIO-treated) ECs (Fig. 2C).
Synthesis and Physicochemical Characterization of Nanoliposomal NTG (NTG-NL). Currently 
available NTG formulations that aim to treat severe vasoconstriction (angina pectoris) commonly yield a 
cumulative plasma NTG concentration of ~90 μ M (20 mg/L)19–21. Such high NTG doses result in exces-
sive mitochondrial superoxide production that, in turn, leads to impaired NTG sensitivity (tolerance) 
and endothelial dysfunction10–12. Thus to successfully leverage the important therapeutic implications 
of the anti-inflammatory effects of NTG, we employed the principles of nanotechnology to incorpo-
rate NTG within nanoparticles (NPs) as they are known to significantly improve drug efficacy14,15. NPs 
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Figure 2. NTG Enhances Endothelial NO Production. (A) Addition of NTG (5 μ M) to L-NIO-treated 
ECs prevents the loss of endothelial NO production by L-NIO, as determined by NOA measurement of 
extracellular NO (n = 4 replicates per condition). Data normalized with respected to untreated control 
condition (con). **p < 0.01; ***p < 0.001. (B) Fluorescent images of ECs labeled with NO-sensitive dye 
(DAF-FM diacetate) and subsequent image analysis (bar graph; n = at least 30 cells) confirms that NTG-
mediated increase in NO results from greater endothelial NO synthesis. Scale bar: 25 μ m. ***p < 0.001. 
(C) Staining of U937 cell-EC co-cultures with anti-ICAM-1 and phalloidin (to label actin) and subsequent 
image analysis (bar graph; n ≥ 30 cells), as described in Materials and Methods, indicates that the anti-
inflammatory effect of NTG (5 μ M) correlates strongly with its ability to prevent ICAM-1 clustering induced 
by NO deficiency (L-NIO treatment). ***p < 0.001. Scale bar: 25 μ m. Data are expressed as mean ± SEM.
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were made either from an amphiphilic block copolymer poly(D,L-lactide-co-glycolide)-block-poly(eth-
ylene glycol) (PLGA-b-PEG) or from a combination of four lipids (DPhPC, POPC, Cholesterol, and 
DHPE-Texas Red). The two distinct building blocks were chosen because the NTG molecule contains 
both hydrophilic and hydrophobic residues (Fig. 3A). Thus, we reasoned that if NTG exhibits predom-
inantly hydrophobic characteristics, it would preferentially incorporate within the hydrophobic PLGA 
core of the PLGA-b-PEG nanoparticle; if it exhibits greater hydrophilicity, it would incorporate within 
the hydrophilic core of the lipid nanoparticle (nanoliposomes; NL) (Fig. 3B).
Figure 3. Synthesis and Physicochemical Characterization of Nanoliposomal NTG (NTG-NL).  
(A) Schematic of NTG molecule depicting the hydrophobic (-CH2-CH2-) and hydrophilic (ONOO−) groups. 
(B) For incorporation within nanoliposomes (NLs), NTG was mixed with four lipids viz. DPhPC, POPC, 
Cholesterol, and DHPE-Texas Red, which self-assemble to form nanoliposomes in an aqueous solution. For 
incorporation within polymeric NPs, NTG was mixed with an amphiphilic PLGA-b-PEG block copolymer 
that spontaneously self-assembles in aqueous solution to form NPs with a hydrophobic PLGA core and 
hydrophilic PEG surface. ESI-Mass Spec. measurements reveal that at 10% w/w initial NTG loading,  
(C) NLs exhibit successful incorporation (~37% incorporation efficiency), while (D) polymeric NPs failed 
to incorporate NTG. (E) Dynamic Light Scattering (DLS) analysis reveals that both blank and NTG-loaded 
NLs exhibit similar diameter (~155 nm). (F) Size distribution of NL was independently confirmed using 
scanning electron microscope (SEM). Scale bar: 200 nm. Data are expressed as mean ± Std Dev.
www.nature.com/scientificreports/
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Analysis of electrospray ionization-mass spectroscopy (ESI-MS) peaks revealed differences in NTG 
uptake into nanoliposomes (NLs) vs polymeric NPs. While NLs demonstrated a dose-dependent increase 
in NTG loading (Fig.  3C and Supplementary Table S1), polymeric NPs failed to incorporate NTG 
(Fig.  3D). These findings, which represent the first attempt to encapsulate NTG within a nanocarrier, 
identify NLs as the preferred vehicle for NTG packaging and delivery. Interestingly, although NTG incor-
poration within NLs understandably increased with increasing loading, the incorporation efficiency was 
highest (~37% of initial NTG added) at an intermediate NTG loading of 10% (w/w) (Supplementary 
Table S1). Based on these findings, 10% (w/w) NTG-NL were chosen as the preferred nanoformulation 
for subsequent cell functional studies.
The size distribution profile of NLs, obtained using dynamic light scattering (DLS), revealed an aver-
age diameter of 157 ± 36 nm and 154 ± 33 nm for blank and NTG-NL, respectively (Fig. 3E), which was 
independently confirmed by scanning electron microscopy (Fig. 3F).
Cellular Uptake of Nanoliposomes (NL). Following NL synthesis, we examined their uptake by 
cultured ECs. Fluorescein-loaded NLs (5 μ g/ml) were added to ECs for 5, 15, 30, or 60 min prior to fixa-
tion and imaging. Quantification of intracellular fluorescence intensity measurements revealed that nan-
oliposomal uptake peaked at approximately 30 min, followed by a plateau between 30–60 min (Fig. 4A). 
These internalized NLs expectedly localized within the acidic endocytic organelles viz. lysosomes and 
endosomes that line the perinuclear region (Fig. 4B). Notably, although the amount of internalized NLs 
increased at higher NL doses, the percent internalization was highest (9%) at 5 μ g/ml (Supplementary 
Table S2). Based on these observations of nanoliposomal uptake, all subsequent in vitro cell functional 
studies were performed following 30 min treatment with a 5 μ g/ml dose of NL.
NTG-NL Exerts Superior Anti-inflammatory Effects. For NTG-NL to be truly effective as an 
anti-inflammatory therapy, it is essential that blank NLs exert no inflammatory effects. To confirm this, 
we analyzed U937 cell adhesion to ECs treated with blank NLs. Quantification of adherent U937 cells 
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Figure 4. Cellular Uptake of Nanoliposomes. (A) Spectrophotometer measurements of internalized 
fluorescently-labeled nanoliposomes (NL) reveal time-dependent uptake of NLs by cultured ECs (n = 5 
replicates per condition). ***p < 0.001; ns, no significance. (B) Fluorescent images of internalized NLs 
indicate strong colocalization with LysoTracker Red™-labeled endocytic vesicles (lysosomes and endosomes). 
Scale bar: 10 μ m. Data are expressed as mean ± SEM.
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revealed that U937 cell adhesion to blank NL-treated ECs is comparable to that seen on untreated ECs 
(Fig. 5A). Further, treatment of ECs with blank NLs failed to suppress L-NIO-induced increase in U937 
cell-EC adhesion (Fig. 5A). These data clearly indicate that blank NLs are totally inert to ECs.
Nanoliposomes are known to enhance drug efficacy (i.e. reduce effective drug dose) by simultaneously 
increasing drug half-life and facilitating rapid cellular uptake13–15. Thus, we asked whether the inter-
nalized NTG-NLs could improve the anti-inflammatory effect of incorporated NTG. Our studies indi-
cate that addition of NTG-NL at 5 μ g/ml to L-NIO-treated ECs produced a significant (52%; p < 0.001) 
prevention of U937 cell adhesion to ECs, with the number of adherent U937s returning to the levels 
seen on untreated ECs (Fig. 5B). This reduction in U937 cell-EC adhesion by NTG-NL was comparable 
to the anti-inflammatory effect produced by a 5 μ M (0.284 μ g total) dose of free NTG. Determination 
of the total amount of NTG delivered intracellularly through nanoliposomal formulation revealed that 
NTG-NL produced its potent anti-inflammatory effect at an equivalent NTG dose of 0.07 μ M (0.004 μ g 
total), which is 70-fold less than the effective dose of free NTG (5 μ M) (refer to Materials and Methods). 
In other words, NTG-NL was found to be 70-fold more effective than free NTG in suppressing endothe-
lial activation. That this remarkable increase in therapeutic efficacy resulted primarily from nanoformu-
lation of NTG was confirmed by the observation that an equivalent amount (0.07 μ M) of free NTG failed 
to produce a significant anti-inflammatory effect (Fig. 5B). NTG-NLs stored at 4 °C and 37 °C for 24 hr 
exerted similar anti-inflammatory effects (Supplementary Fig. S2), thereby confirming past findings that 
nanoliposomes act as stable drug carriers22. Moreover, similar to free NTG, the anti-inflammatory effects 
of NTG-NL correlated strongly with its ability to enhance endothelial NO production (Fig.  6A,B) and 
suppress ICAM-1 clustering (Fig. 6C).
NTG-NL Prevents Endothelial Superoxide Formation Associated with High NTG Dose. High 
plasma concentrations of NTG that result from the use of conventional NTG formulations (e.g. transder-
mal patches and tablets) are known to cause significant increase in mitochondrial superoxide formation 
that, in turn, leads to impaired NTG bioconversion to NO (tolerance) and endothelial dysfunction10–12. 
Consistent with these observations, treatment of ECs with a 100 μ M dose of free NTG, which is com-
parable to the high doses used in NTG therapies, caused a 2-fold (p < 0.001) increase in mitochondrial 
Con L-NIO Blank NL 
0 
25 
50 
75 
# 
U
93
7 
L-NIO  
+  
Blank NL 
 ** 
A 
L-NIO - + + + 
0.07 µM
(NTG-NL) 
+ 
0 
25 
50 
75 
100 
 ***  *** 
5 µM
(Free NTG) 
# 
U
93
7 
 
B 
0.07 µM
(Free NTG) NTG - - 
ns 
ns 
ns 
 *** 
Figure 5. NTG-NL Exerts Superior Anti-inflammatory Effects. (A) Blank NLs are inert to ECs as cells 
treated with blank NLs exhibit neither an increase in U937 cell adhesion (with respect to control) nor a 
decrease in L-NIO-induced U937 cell adhesion (n = 10 fields of view). **p < 0.01; ns, no significance.  
(B) Addition of 5 μ g/ml NTG-NL (≡ 0.07 μ M NTG) to L-NIO-treated ECs significantly inhibits U937 cell-EC 
adhesion, which is comparable to the inhibition produced by a 70-fold greater dose of free NTG (5 μ M). 
Free NTG dose of 0.07 μ M does not produce a significant anti-inflammatory effect. (n = 10 fields of view). 
***p < 0.001; ns, no significance. Data are expressed as mean ± SEM.
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superoxide formation (Fig. 7A,B), as determined by quantitative analysis of cells labeled with MitoSOX™, 
a fluorescent mitochondrial superoxide-sensitive dye that is widely used to measure mitochondrial reac-
tive oxygen specie (ROS) production in response to high-dose NTG treatment23. Notably, as shown in 
Supplementary Fig. S3, this difference in MitoSOX™ fluorescence intensity is a true reflection of the dif-
ferences in mitochondrial superoxide production and not an artifact resulting from varying cell density 
or spreading.
Since NTG-NL exhibited potent anti-inflammatory effects at a dose 70-fold lower than that of free 
NTG, we next asked whether a similar 20-fold increase in NTG-NL dose would ameliorate the adverse 
effects associated with high-dose NTG therapies. Indeed, we found that NTG-NL did not elicit any 
increase in mitochondrial superoxide production when used at the 20-fold higher dose of 100 μ g/ml 
(Fig. 7A,B).
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Figure 6. NTG-NL Enhances Endothelial NO Production. (A) Immunofluorescent staining of ECs 
labeled with NO-sensitive dye (DAF-FM diacetate) and (B) subsequent image analysis (bar graph; n = at 
least 30 cells) confirms that, like free NTG, NTG-NL enhances NO production in L-NIO-treated cells. 
Scale bar: 25 μ m. **p < 0.01; ***p < 0.001; ns, no significance. (C) Immunofluorescent staining of U937 
cell-EC co-cultures for ICAM-1 and subsequent fluorescent intensity measurement (bar graph; n = at least 
20 cells) reveals that, like free NTG (5 μ M), NTG-NL (5 μ g/ml) suppresses ICAM-1 clustering induced 
by NO deficiency (L-NIO treatment). **p < 0.01; ***p < 0.001; ns, no significance. Data are expressed as 
mean ± SEM.
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Consistent with the view that excessive mitochondrial superoxide production at high NTG doses 
inhibits ALDH-2 activity and, thus, NTG bioconversion to NO, we observed a drastic loss (~2-fold 
decrease; p < 0.001) in the anti-inflammatory effects of free NTG at 100 μ M (Fig.  7C). In contrast, 
NTG-NL retained its potent immunosuppressive effects (84% inhibition; p < 0.001) when used at a 
20-fold higher dose of 100 μ g/ml (Fig.  7D). We further confirmed NTG-NL’s ability to prevent loss of 
NTG sensitivity at high doses using an ex vivo arterial vasorelaxation assay. This assay, which is widely 
used to evaluate NTG tolerance10,24, demonstrated that while arteries pretreated with 100 μ M free NTG 
exhibited a significant loss of NTG sensitivity (IC50 increasing from 0.2 to 15 μ M), those treated with 
NTG-NL at an equivalent 20-fold higher dose maintained their normal vasodilatory responsiveness 
(Supplementary Fig. S4).
Figure 7. NTG-NL Prevents Endothelial Superoxide Formation Associated with High NTG Dose. 
(A) Representative fluorescent images of MitoSOX™-labeled ECs and (B) subsequent quantification (bar 
graph; n ≥ 30 cells) indicate that addition of 20-fold higher dose (100 μ M) of free NTG to L-NIO-treated 
ECs significantly increases mitochondrial superoxide formation while similar increase in NTG-NL dose 
(0.07 μ M to 1.4 μ M) produces no effect. Scale bar: 100 μ m. ***p < 0.001; ns, no significance. (C) The high 
dose (100 μ M) of free NTG fails to suppress U937 monocytic cell adhesion to L-NIO-treated ECs (n = 10 
fields of view). ***p < 0.001; ns, no significance. (D) Unlike free NTG, NTG-NL continues to exert potent 
anti-inflammatory effects on L-NIO-treated ECs even at a 20-fold higher dose (n = 10 fields of view) with all 
NTG-NL doses demonstrating similar inhibition of U937 adhesion. Therapeutic dose is indicated in bold. 
***p < 0.001; ns, no significance. Data are expressed as mean ± SEM.
www.nature.com/scientificreports/
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Discussion
This study demonstrates a proof-of-principle for a new nanoliposomal NTG formulation that amplifies 
the newly-identified anti-inflammatory properties of NTG while significantly ameliorating the adverse 
effects associated with high NTG doses. NTG is one of the most commonly used organic nitrates in the 
clinic where it is intended to mimic the vasodilatory effects of endothelium-derived NO19. When com-
pared with inorganic nitrites/nitrates, NTG produces a significantly greater and rapid yield of NO6, which 
explains its superior vasodilatory properties. Since endothelial NO also exhibits potent anti-inflammatory 
effects, here we asked whether NTG can suppress leukocyte-EC adhesion.
Our findings reveal that NTG significantly inhibits U937 cell adhesion to NO-deficient ECs. This 
anti-inflammatory effect of NTG occurred in a dose-dependent manner, with significance achieved at a 
dose of 5 μ M. That a higher NTG dose is required to achieve significant anti-inflammatory effect than 
is required for vasodilation (IC50 = 0.2 μ M) may be attributed to the fact that these different therapeutic 
effects of NTG involve different target cell types with potentially distinct NTG sensitivity. For instance, 
NTG exerts its anti-inflammatory effect on luminal ECs that undergo activation to promote monocyte 
adhesion25 while its vasodilatory effects are targeted towards abluminal smooth muscle cells that exhibit 
excessive vasoconstriction1. Thus, it is plausible that smooth muscle cells are more sensitive to NTG 
than ECs, and thereby require lower doses to exhibit NTG-dependent vasodilation. It should, however, 
be noted the effective anti-inflammatory NTG dose of 5 μ M still lies within the dose range (0.09–90 μ M) 
that is widely used for current NTG therapies19–21.
Further, consistent with past findings that suppression of monocyte-EC adhesion by NO results from 
inhibition of endothelial CAM clustering17, NTG treatment produced significant inhibition of ICAM-1 
clustering on EC surface. ICAM-1 is a key EC surface marker that facilitates leukocyte-EC adhesion 
by undergoing clustering on EC surface, which results in the formation of an ICAM-1 binding pocket 
for firm leukocyte docking and adhesion26. Past studies have indicated that the ability of NO to inhibit 
ICAM-1 clustering likely results from suppression of Rho/ROCK-dependent actin cytoskeletal reorgan-
ization at the site of monocyte-EC adhesion27,28.
Although inorganic nitrites have been shown to exert anti-inflammatory effects4, to our knowledge, 
this is the first report indicating that NTG also exhibits similar properties. Coupled with previous find-
ings that (1) NTG activates eNOS8,9, the major NO-producing enzyme in ECs that is impaired in inflam-
matory conditions such as PAH1 and diabetes3, and (2) NTG mimics the anti-coagulating properties 
of NO to prevent inflammation-associated hypercoagulopathy29, the current findings provide further 
rationale for investigating the use of NTG for anti-inflammatory therapies.
NTG undergoes rapid (within 15–30 min) clearance from bloodstream30. To address this issue, cur-
rent NTG formulations are commonly administered at high doses (up to 90 μ M)19–21. It is, therefore, 
likely that similar high NTG doses may be necessary to achieve its potent anti-inflammatory effects. 
However, this approach poses a limitation in that such high NTG doses lead to excessive mitochondrial 
superoxide production, which greatly limit NTG’s therapeutic efficacy10,12. Mitochondrial superoxide, a 
reactive oxygen species that is formed as a byproduct during NTG bioconversion to NO, inhibits the 
activity of mitochondrial aldehyde dehydrogenase (ALDH-2)10,12, the chief enzyme responsible for NTG 
bioconversion. Thus, excessive amounts of mitochondrial superoxide generated in response to high NTG 
doses significantly impairs ALDH-2 activity and, as a consequence, NTG bioconversion and sensitivity12. 
Indeed, our studies confirmed that raising the dose of free NTG from 5 μ M to 100 μ M led to a significant 
increase in mitochondrial superoxide production that, in turn, correlated with a significant loss in the 
anti-inflammatory effects of NTG.
To improve the benefit/risk profile of NTG therapy, we leveraged the principles of nanotechnology 
to develop a new nanoliposomal NTG formulation (NTG-NL) that undergoes rapid intracellular uptake 
via the conventional clathrin-mediated pathway31 and demonstrates a remarkable 70-fold increase in 
drug efficacy. Such a tremendous increase in drug efficacy is the hallmark of nanocarrier-mediated drug 
delivery, which is known to enhance drug half-life and promote rapid cellular uptake and bioavailability 
of encapsulated drugs14,15. Importantly, the significant enhancement in NTG-NL bioactivity and result-
ant lowering of the effective therapeutic dose meant that, unlike free NTG, NTG-NL did not elicit an 
increase in mitochondrial superoxide production even at very high (20-fold greater) dose. This observa-
tion is supported by findings that, in contrast to free NTG, NTG-NL treatment at a high dose did not 
exhibit any loss of anti-inflammatory effect in vitro or loss of vasorelaxation response in isolated pul-
monary arteries. Taken together, these findings implicate NLs as an effective NTG delivery system that 
has the potential to amplify the newly-identified anti-inflammatory effects while addressing the adverse 
effects associated with high NTG doses.
The in vitro and ex vivo studies performed here are widely used to examine the effects of NTG on the 
vasculature12,23. However, to fully establish the translational potential of nanoliposomal NTG, the current 
proof-of-concept studies need to be validated in appropriate animal models of vascular inflammation. 
NTG-NL are expected to be biocompatible as the lipids used to synthesize these nanoliposomes are 
found in cell membranes32. This excellent biocompatibility is an important reason why liposomes are 
widely used as drug carriers in pharmaceutical industry14,32. Further, the size (~150 nm dia.) of NTG-NL 
is suitable to achieve a long circulation time14,33. Thus, the proof-of-concept studies described here set the 
stage for the development of site-targeting NTG nanotherapeutics that can further improve the efficacy 
of nanoliposomal NTG by simultaneously increasing drug half-life, localizing drug delivery to sites of 
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inflammation, and reducing undesirable off-target effects. As we and others have previously shown15,34, 
such site-targeting can be accomplished by tethering unique site-targeting moieties (peptides, aptamers 
or antibodies)14,15 on the nanoparticle surface that can guide the nanotherapeutic selectively to desired 
vascular sites and facilitate local drug delivery and therapeutic effects. Thus, by simultaneously leverag-
ing the newly-identified anti-inflammatory and well-known vasodilatory properties of NTG, such smart 
nanomedicine approaches may provide a superior therapeutic strategy for effective management of PAH 
that is characterized by both chronic pulmonary arterial inflammation and vasoconstriction35.
Materials and Methods
Cell Culture. Human microvascular endothelial cells (HMEC-1) were purchased from the Center for 
Disease Control (CDC)36 and cultured on gelatin-coated tissue culture dishes in growth medium com-
posed of MCDB-131 (VWR International, USA) supplemented with 10% FBS (Fisherbrand, USA), 2 mM 
L-Glutamine (Invitrogen, USA), 1× antimycotic/antibiotic mixture (Life Technologies, USA), 10 ng/ml 
huEGF (Millipore, USA) and 1 μ g/ml Hydrocortizone (Sigma Aldrich, USA). Human U937 monocytic 
cells were purchased from ATCC (Manassas, VA, USA) and cultured in suspension in growth medium 
composed of RPMI 1640 (Fisherbrand, USA) supplemented with 2 mM L-Glutamine (Invitrogen), 10 mM 
HEPES (Fisherbrand, USA), 10% FBS (Fisherbrand), antimycotic/antibiotic mixture (Life Technologies, 
USA), 1 mM sodium pyruvate (Life Technologies, USA) and 4.5 mg/ml glucose (Sigma Aldrich, USA).
Nanoparticle (NP) Formulation. To synthesize NTG-loaded polymeric nanoparticles (NP), block 
co-polymer PLGA (17 kDa)-PEG-COOH (3.4 kDa) (75:25), Advanced Polymer Materials Inc., QC, 
Canada) was dissolved in DMSO (Sigma Aldrich, USA) at a final concentration of 1 mg/ml15, followed by 
addition of NTG at 10% w/w. NPs were obtained by dialysis using Spectra/Por 6 dialysis membrane (1 kDa 
MWCO; VWR, USA) where the NTG-polymer solution was dialyzed against distilled water (5 L) at room 
temperature, which also removed excess NTG. To synthesize NTG-loaded nanoliposomes (NTG-NL), 
four lipid molecules viz. 1,2-di-(3,7,11,15-tetramethylhexadecanoyl)-sn-glycero-3-phosphocholine 
(DPhPC; Avanti Lipids, USA), 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine 
(POPC; Avanti Lipids, USA), Cholesterol (Sigma Aldrich, USA), and 1,2-dihexadecanoyl-sn-glycero-3-p
hosphoethanolamine-triethylammonium salt (Texas Red-DHPE; Invitrogen, USA) were dissolved in 
chloroform at a molar ratio of 6:2:2:0.2, respectively, and purged with Nitrogen (N2) to evaporate the 
chloroform. The resulting lipid cake was placed under vacuum for at least two hours prior to rehydra-
tion in aqueous NTG (5, 10 and 25% w/w of total lipid; Cerilliant, USA) or Fluorescein (1 mM; Sigma 
Aldrich, USA) solution to obtain a final 1 mg/ml drug- or dye-loaded liposome suspension. To obtain 
NTG-NLs, these liposome suspensions underwent five freeze-thaw cycles in liquid N2 followed by eight 
extrusion cycles through a 100 nm polycarbonate membrane filter (Avanti Lipids, USA). Unincorporated 
NTG or fluorescein was discarded by spinning down NTG-NLs for two hours at 60,000 rcf using a refrig-
erated ultracentrifuge (Beckman Coulter, USA) and decanting the supernatant. The final NTG-NL pellet 
was suspended at 1 mg/ml in water and stored at 4 °C until use.
NTG Incorporation Efficiency. To determine NTG incorporation efficiency within polymeric NPs 
and NTG-NLs, pellets of polymeric NP (1 mg) or NTG-NL (200 μ g) were dissolved in 100% methanol 
and analyzed using electron spray ionization-mass spectroscopy (ESI-MS; Agilent Technologies).
NTG (MW 227.1 Da) was ionized by trifluoroacetic acid (MW: 112.9 Da) and the signature NTG 
mass/charge spectrum peak was detected at 339.9 mass/charge (m/z; charge z = 1 coulomb). Area under 
the NTG peak was measured for both the initial and incorporated NTG and their ratio was calculated 
to determine % NTG incorporation efficiency.
Nanoliposome (NL) Size and Morphology Characterization. Blank NL and NTG-NL suspen-
sions were prepared at 0.5 mg/ml in distilled water and size distribution measured by dynamic light 
scattering (DLS) using a Delsa Nano C Particle Analyzer (Beckman Coulter, USA). Microsoft Excel and 
Origin Pro software were used to acquire and analyze the data. NL morphology was analyzed using scan-
ning electron microscopy (SEM; FEI NNS450) operated in high vacuum mode. For SEM samples, NLs 
were fixed in 2.5% glutaraldehyde (Electron Microscopy Sciences, USA) for 2 hr at 4 °C. After fixation, 
10 ul of NLs were added to Poly-L-Lysine (Sigma-Aldrich, USA)-coated 12 mm glass coverslips, allowed 
to settle for 5 minutes, and subjected to critical-point drying in liquid CO2 (Critical-point-dryer Balzers 
CPD0202). Samples were then sputter-coated with chromium for 30 sec and analyzed using the SEM 
instrument described above.
Nanoliposome (NL) Uptake. To determine the rate of NL uptake by ECs, Texas Red®-labeled NLs 
were diluted in EC culture medium at 5 μ g/ml and added to ECs for 5, 15, 30 or 60 min at 37 °C. To 
quantify the extent of NL uptake at different doses, Texas Red®-labeled NLs at 5, 10, 50 or 100 μ g/ml were 
added to EC monolayer for 30 min at 37 °C. After treatment, non-internalized NLs were removed by rins-
ing ECs twice with PBS, following by culturing ECs in phenol-red free MEM media (Life Technologies, 
USA) supplemented with 2 mM L-Glutamine and 10% FBS and measurement of fluorescence intensity 
by Wallac 1420 Victor2 fluorescent microplate plate reader (Perkin Elmer, USA). To determine % NL 
uptake, fluorescence intensity of NL-treated ECs was divided by the intensity obtained from unrinsed 
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samples. Further, to determine whether NTG-NLs were successfully endocytosed, ECs treated with 
fluorescein-incorporated NLs were stained with LysoTracker® Deep Red (Invitrogen, USA) to label acidic 
organelles (lysosomes and endosomes).
Monocyte-EC Adhesion Assay. To examine the effects of NTG on monocyte-EC adhesion, conflu-
ent EC monolayers were either serum-starved (MCDB-131, 2.5% FBS, and 1× antibiotic/antimycotic 
supplement) overnight and treated with 10 ng/ml TNF-α (eBiosciences, USA) for 4 hr or treated with 
5 mM L-NIO (N5 - (1- iminoethyl)- L- ornithine; selective eNOS inhibitor; Cayman Chemical, MI, 
USA) ± varying doses of NTG (0, 0.07, 0.2, 1 or 5 μ M; Cambridge Isotope, MA) for overnight in regular 
medium, followed by addition of fluorescently-labeled U937 monocytic cells at a density of 130,000 cells/
cm2. To confirm that NTG-NLs can be readily uptaken by ECs and processed to release NO, some EC 
cultures were also treated with L-NIO ± NTG-NL for 4 hr prior to plating fluorescently-labeled U937 
cells. After 30 min of U937 cell -EC interaction at 37 °C, U937 suspension was removed and the EC mon-
olayers gently rinsed twice with PBS (to remove unbound U937s) prior to fixation in 1% paraformalde-
hyde (PFA; Electron Microscopy Sciences, USA). Fluorescent images (10 per condition) of labeled U937 
cells were then acquired using a Nikon Eclipse Ti microscope (Nikon, Japan) fitted with a Nikon Digital 
Sight DS-Qi1Mc camera and the number of adherent U937s was counted using ImageJ software (NIH). 
For experiments involving NLs, ECs were incubated with 5 μ g/ml of blank or 10% (w/w) NTG-loaded 
nanoparticles (NTG-NL) for 30 minutes at 37 °C, rinsed with PBS to remove excess NLs, and cultured 
overnight prior to addition of fluorescently-labeled U937 cells (as described above).
Determination of NTG-NL’s therapeutic efficacy. The therapeutic efficacy of NTG-NL was 
determined by taking a ratio of the net free NTG dose required to exert significant anti-inflammatory 
effect with the net NTG dose needed to exert the same effect when delivered within NL. Significant 
anti-inflammatory effect was achieved at a free NTG dose of 5 μ M (1.136 μ g/ml), which results in a net 
NTG dose of 0.284 μ g per 250 μ L of EC culture medium. In comparison, considering a 10% (w/w) initial 
NTG loading, 36.4% NTG incorporation efficiency within NLs, and a 9% intracellular uptake, NTG-NLs 
exhibit similar anti-inflammatory effect at a dose of 5 μ g/ml (0.182 μ g/ml of NTG), which results in a net 
intracellular NTG dose of 0.004 μ g per 250 μ L of EC culture medium. The ratio of net free NTG dose 
(0.284 μ g) to net NTG dose delivered via NLs (0.004 μ g) was used to determine the fold-increase in NTG 
efficacy achieved with NTG-NLs.
Measurement of EC-derived NO. Two independent methods were used to measure the amount 
of NO produced by ECs. In the first method, ECs were treated overnight with L-NIO (5 mM) ± NTG 
(5 μ M) or NTG-NL (10 μ g/ml), followed by incubation with a NO-sensitive fluorescent dye DAF-FM 
diacetate (2 μ M; Life Technologies, USA) for 20 minutes at 37 °C. Following dye loading, ECs were again 
treated with L-NIO and NTG during a recovery phase for an additional 1 hr in regular growth medium. 
EC culture media was then rinsed once with Krebs-Henseleit Buffer (KHB) containing 125 mM NaCl, 
4.74 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4 1.2 mM MgSO4, 5 mM NaHCO3 and 10 mM Glucose 
(Sigma Aldrich, USA), replaced with fresh KHB and immediately subjected to live cell fluorescence 
imaging using Nikon Eclipse Ti microscope. At least 30 cells per condition were analyzed for total cell 
fluorescence using ImageJ software (NIH). For the second method, a Nitric Oxide Analyzer (NOA; 
Sievers, USA) was used to measure EC-secreted NO in culture medium. For this measurement, con-
fluent ECs were treated overnight with either L-NIO (5 mM) ± NTG (5 μ M) or NTG alone, followed 
by sequential 1 hr incubations with KHB without and with L-NIO ± NTG at 37 °C. KHB conditioned 
medium (4 replicates per condition) was then collected and analyzed using NOA.
ICAM-1 Clustering. ECs were grown to confluence on glass coverslips under normal growth condi-
tions and treated with L-NIO (5 mM) ± [NTG (5 μ M) or NTG-NL (5 μ g/ml)] for 24 hr. Next, a monocyte 
adhesion assay was performed (as described earlier) and the U937 cell-EC cocultures fixed, permea-
bilized with 0.1% Triton X-100, blocked with 2% bovine serum albumin (BSA; Millipore, USA), and 
sequentially incubated with primary anti-ICAM-1 mouse antibody (Santa Cruz Biotechnology, USA) and 
secondary FITC-conjugated DyLight 488 anti-mouse IgG (Vector Labs, USA). To visualize actin micro-
filaments, U937 cell-EC cocultures were incubated with Alexa Fluor 594-Phalloidin (BD Biosciences, 
USA). Coverslips were mounted onto glass slides and fluorescence images (15 per condition) were taken 
using a Nikon Eclipse Ti microscope fitted with a Nikon Digital Sight DS-Qi1Mc camera. ICAM-1 clus-
tering index was determined by measuring ICAM-1 fluorescence intensity (from n ≥ 10 images) at the 
U937-EC adhesion site and normalizing it to the average ‘background’ intensity measured from three 
neighboring EC cytoplasmic sites.
ICAM-1 Expression. ECs were plated to confluence under normal growth conditions and treated 
with L-NIO (5 mM) ± NTG (5 μ M) overnight. ECs were then detached and sequentially labeled with pri-
mary anti-ICAM-1 antibody (Santa Cruz Biotechnology, USA) for 20 min, followed by FITC-conjugated 
DyLight 488 anti-mouse IgG (Vector labs. USA). Next, ECs were fixed with 1% PFA, detected by a Cell 
Lab Quanta SC flow cytometer (Beckman Coulter, CA), and analyzed by FlowJo software (Treestar Inc, 
CA).
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Detection of Endothelial Mitochondrial Superoxide Production. ECs were plated at sub- 
confluence on gelatin-coated MatTek dishes under normal culture conditions and subjected to overnight 
treatment with either L-NIO (3 mM) ± [NTG (5, 25, or 100 μ M) or NTG-NL (5, 50 or 100 μ g/ml)]. 
To detect mitochondrial superoxide, ECs were labeled with MitoSOX™ (Life Technologies, USA), a mito-
chondrial superoxide-sensitive fluorescent dye that is widely used to measure mitochondrial ROS pro-
duction under various conditions, including NTG treatment23. ECs were labeled with MitoSOX™ Red at 
a final dose of 5 μ M in KHB for 10 min at 37 °C, rinsed three times with KHB to remove excess dye and 
placed at 37 °C in KHB for an additional 10 min prior to live cell imaging. Fluorescence images (six per 
condition) were acquired using Nikon Eclipse Ti microscope and total cell fluorescence intensity from 
at least 20 cells was analyzed using ImageJ software.
Pulmonary Artery Ring Preparation and Isometric Tension Measurements. All animal proce-
dures were in accordance with the Animal Welfare Act, the Guiding Principles in the Care and Use of 
Animals approved by the Council of the American Physiological Society, the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals, and Loma Linda University Institutional Animal 
Care and Use Committee (IACUC). Pregnant ewes were anesthetized with ketamine (10 mg/kg, IV) and 
midazolam (5 mg/kg, IV) and anesthesia maintained with inhalation of 1-3% isoflurane in O2 through-
out surgery as required. Ewes and Fetuses were euthanized with an overdose of Euthasol (pentobarbital 
sodium, 100 mg/kg) and phenytoin sodium (10 mg/kg; Virbac, Ft. Worth, TX).
To assess arterial vasorelaxation in response to NTG treatment, pulmonary arteries (4th–5th order) 
were harvested from newborn fetal sheep (gestational period between 138–141 days), dissected free of 
parenchyma and cut into 5 mM long rings (at least eight per condition) in ice-cold HEPES buffer (Sigma 
Aldrich, USA). Rings were then preincubated in L-NIO (1 mM) ± [NTG (5 or 100 μ M) or NTG-NL (5 
or 100 μ g/ml)] for 4 hr at 37 °C; free NTG at 100 μ M has previously been reported to induce NTG tol-
erance of isolated arterial rings within 4 hr12. Following treatment, rings were mounted onto tungsten 
wires under 0.5 g of resting tension in organ baths containing KHB, gassed with 95% O2–5% CO2, and 
maintained at 37 °C. Arterial rings were rinsed once with KHB, allowed to equilibrate for at least 30 min-
utes, and retensioned prior to addition of 125 mM KCl (Sigma Aldrich, USA) to ensure rings were still 
functional. Rings were rinsed three times to remove KCl, allowed to relax, and preconstricted with 10 μ M 
Serotonin (Tocris Bioscience, USA) to achieve 100% contraction. Rings were then exposed to increas-
ing concentrations of free NTG (1 nm to 100 μ M) and subsequent recordings of concentration-response 
curves were acquired using a force displacement transducer (AD Instruments, New Zealand) and ana-
lyzed using Prism (Graphpad Software Inc).
Statistics. All data were obtained from multiple replicates (as described in the appropriate sections) and 
expressed as mean ± standard error of mean (SEM). Statistical significance was determined using analysis 
of variance (ANOVA; InStat; Graphpad Software Inc.) followed by a Tukey multiple comparison post-hoc 
analysis. Results demonstrating significance were represented as *p < 0.05, **p < 0.01, or ***p < 0.001.
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